Innovative Pricing and Payment Models for Health Technologies

By João L. Carapinha

October 22, 2024

The article titled “Design and Features of Pricing and Payment Schemes for Health Technologies,” centers on the crucial topic of pricing and payment (P&P) schemes for health technologies in the healthcare sector. The discussion encompasses key aspects that influence this domain, providing insights on how these schemes can effectively address current challenges.

Objective

The article aims to map existing types of pricing and payment schemes for health technologies while proposing a new, flexible, need-driven classification system that enhances understanding and applicability.

Context

Given the increasing clinical and financial uncertainty in the healthcare sector, innovative pricing and payment schemes are being explored as potential solutions to these persistent challenges.

Current Schemes

The article conducts a scoping review to identify and categorize the various P&P schemes currently in use for health technologies. This includes different models such as:

  • Fixed pricing
  • Value-based pricing
  • Risk-sharing agreements
  • Pay-for-performance models
  • Subscription-based models

Proposed Classification

The authors propose a new classification system that is both flexible and need-driven. This system is designed to help policymakers, healthcare providers, and manufacturers navigate the complex landscape of P&P schemes more effectively. It considers various factors, including the type of health technology and the specific needs of different healthcare systems.

Key Features

The article highlights several key features of effective pricing and payment schemes, which include:

  • Flexibility: The ability to adapt to evolving healthcare needs and financial constraints.
  • Value-Based: Schemes that tie payments to actual health outcomes or to the value delivered by the health technology.
  • Risk Management: Mechanisms that distribute risk among manufacturers, payers, and providers.
  • Innovation Incentives: Schemes designed to encourage the development and adoption of new health technologies.

Implications

The proposed classification and analysis of P&P schemes have significant implications for healthcare policy, practice, and research. It can aid in:

  • Improving the sustainability of healthcare systems
  • Enhancing access to innovative health technologies
  • Aligning payments with health outcomes
  • Reducing financial uncertainty for various stakeholders involved.

In summary, the article provides a comprehensive framework for understanding and improving the design and implementation of P&P schemes in the healthcare sector, ultimately serving as a vital tool in addressing current challenges. The focus on pricing and payment schemes is essential for fostering effective health technology utilization and ensuring ongoing innovation.

Reference url

Recent Posts

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

Pluvicto prostate cancer trial
        

Pluvicto Prostate Cancer Trial: Phase III Results

🔍 Have you heard about the latest breakthrough in prostate cancer treatment?

Novartis’s Pluvicto™ has shown significant clinical benefits in earlier-stage prostate cancer, highlighting its potential to transform treatment paradigms for patients with metastatic hormone-sensitive prostate cancer. With promising data on radiographic progression-free survival, the implications for healthcare systems are profound, pushing us toward more effective and targeted therapies for this pressing health challenge.

Dive into the full article to explore how Pluvicto™ is shifting the landscape of prostate cancer management!

#SyenzaNews #oncology #HealthcareInnovation

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.